Breaking barriers: NEK2 inhibition shines in multiple myeloma treatment

Christopher Lischer; Heiko Bruns

doi:10.1016/j.xcrm.2023.101237

Breaking barriers: NEK2 inhibition shines in multiple myeloma treatment

Cell Rep Med. 2023 Oct 17;4(10):101237. doi: 10.1016/j.xcrm.2023.101237.

Authors

Christopher Lischer¹, Heiko Bruns²

Affiliations

¹ Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany; Deutsches Zentrum für Immuntherapie (DZI), Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany; Bavarian Cancer Research Center (BZKF), Erlangen, Germany.
² Deutsches Zentrum für Immuntherapie (DZI), Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany; Bavarian Cancer Research Center (BZKF), Erlangen, Germany; Department of Internal Medicine 5, Haematology and Oncology, Uniklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany. Electronic address: heiko.bruns@uk-erlangen.de.

Abstract

In their article, Cheng et al.¹ reveal that NEK2 loss reshapes the tumor microenvironment, reducing tumor-associated macrophages and decreasing T cell exhaustion. They show that this ultimately favors the immune system's anti-cancer response in multiple myeloma.

Publication types

Comment

MeSH terms

Cell Proliferation
Humans
Multiple Myeloma* / drug therapy
Multiple Myeloma* / genetics
NIMA-Related Kinases / genetics
Tumor Microenvironment

Substances

NIMA-Related Kinases
NEK2 protein, human